Join to view full profile
55 Fruit StWac 6255Boston, MA 02114
Phone+1 617-726-2066
Fax+1 617-643-5843
Dr. Chen is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2005 - 2007
Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 2002 - 2005
Harvard Medical SchoolClass of 2002
Certifications & Licensure
MA State Medical License 2004 - 2028
NH State Medical License 2024 - 2024
ME State Medical License Active through 2021
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
Publications & Presentations
PubMed
- 5 citationsVedolizumab for prevention of lower-GI acute GVHD in the Japanese subgroup analysis of the phase 3 GRAPHITE study.Tatsunori Goto, Hiroshi Okamura, Takashi Ikeda, Yasuo Mori, Souichi Shiratori
International Journal of Hematology. 2025-07-01 - 2 citationsA phase I clinical trial of lenalidomide combined with bortezomib for acute myeloid leukemia or myelodysplastic syndrome relapsing after allogeneic stem cell transplan...Brandon J Aubrey, Traci Blonquist, Malgorzata McMasters, Gabriela Hobbs, Steven McAfee
Leukemia Research. 2025-06-01 - 23 citationsLow rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT.Zachariah DeFilipp, Haesook T Kim, Laura W Knight, Suzanne M O'Connor, Shilton E Dhaver
Blood. 2025-05-15
Press Mentions
Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)February 19th, 2023- Discovery May Lead to Expanded Donor Pool for Stem Cell Transplants for Patients with CancerNovember 20th, 2021
- New Phesi Proof of Concept Demonstrates Potential of AI-Powered Digital Twins to Replace External Control Arms in Clinical TrialsJune 26th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: